Anticancer Therapy SMRT-ens Up: Targeting the BCL6-SMRT Interaction in B Cell Lymphoma

Leigh A. Compton; Scott W. Hiebert

doi:10.1016/j.ccr.2010.03.012

Anticancer Therapy SMRT-ens Up: Targeting the BCL6-SMRT Interaction in B Cell Lymphoma

Leigh A. Compton, Scott W. Hiebert

Division of Anatomic and Molecular Pathology (AMP)

Research output: Contribution to journal › Short survey › peer-review

5 Scopus citations

Abstract

Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.

Original language	English
Pages (from-to)	315-316
Number of pages	2
Journal	Cancer Cell
Volume	17
Issue number	4
DOIs	https://doi.org/10.1016/j.ccr.2010.03.012
State	Published - Apr 13 2010

Access to Document

10.1016/j.ccr.2010.03.012

Cite this

@article{b6b7721597f441c68afc500bfa608780,

title = "Anticancer Therapy SMRT-ens Up: Targeting the BCL6-SMRT Interaction in B Cell Lymphoma",

abstract = "Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.",

author = "Compton, {Leigh A.} and Hiebert, {Scott W.}",

year = "2010",

month = apr,

day = "13",

doi = "10.1016/j.ccr.2010.03.012",

language = "English",

volume = "17",

pages = "315--316",

journal = "Cancer Cell",

issn = "1535-6108",

number = "4",

}

TY - JOUR

T1 - Anticancer Therapy SMRT-ens Up

T2 - Targeting the BCL6-SMRT Interaction in B Cell Lymphoma

AU - Compton, Leigh A.

AU - Hiebert, Scott W.

PY - 2010/4/13

Y1 - 2010/4/13

N2 - Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.

AB - Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=77950514654&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2010.03.012

DO - 10.1016/j.ccr.2010.03.012

M3 - Short survey

C2 - 20385356

AN - SCOPUS:77950514654

SN - 1535-6108

VL - 17

SP - 315

EP - 316

JO - Cancer Cell

JF - Cancer Cell

IS - 4

ER -

Anticancer Therapy SMRT-ens Up: Targeting the BCL6-SMRT Interaction in B Cell Lymphoma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this